KOL Views Preview: AbbVie’s ABBV-951 works but will PD patients use it?

ABBV-951 was expected to work better than oral levodopa/carbidopa and it did not disappoint in a Phase III trial for advanced Parkinson’s disease (PD). However, the bigger question was how tolerable the drug-device combination of levodopa and carbidopa prodrugs would be, and a discontinuation rate north of 20% suggests that this could be a real problem.

To provide FirstWord readers with rapid feedback on how ABBV-951 might fit into the treatment landscape, we are hosting an expert call with a key opinion leader (KOL) this week.

Key topics that will be discussed during the call include, among other things… what stands out most about these top-line Phase III results; do you have any lingering questions about ABBV-951’s efficacy profile; initial thoughts on the product’s safety and tolerability; how relevant is the meaningful increase in discontinuations (21.6% versus 1.5% for placebo); might this stand in the way of regulatory approval; what impact will ABBV-951’s risk/benefit profile have on real world use and adoption; where do you see it fitting into the prescribing algorithm; could this eventually be used as front-line therapy; does ABBV-951’s performance change your thoughts on competing continuous infusible programmes from NeuroDerm and/or Dizlin; and are there other therapies in development for PD about which you are more excited?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, we will do our utmost to cover the important issues relating to the use of ABBV-951 and/or other PD therapies.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord Pharma would very much like to receive your feedback and suggestions.